Dutch Startup HeartEye Could Cut Hospital Referrals With a 60-Second Heart Scan at Your GP
Amsterdam, Saturday, 6 June 2026.
HeartEye’s wire-free 12-lead ECG device delivers a full cardiac reading in under one minute — at the GP’s office or at home. With 65% of cardiology referrals in the Netherlands deemed unnecessary, this could reshape how heart conditions are caught early.
A Healthtech Story, Not a Finance One — But the Stakes Are Just as High
This is a healthtech story. HeartEye is an Amsterdam-based medical technology startup developing a mobile cardiac diagnostic device for use in primary care settings [1]. While the innovation sits firmly in the domain of medicine and healthtech — rather than agritech or food — the financial and systemic pressures it seeks to relieve are considerable. In the Netherlands, someone dies from cardiovascular disease every quarter of an hour [1]. That is not merely a clinical statistic; it is a measure of how costly — in human and economic terms — delayed diagnosis can be. HeartEye’s proposition is straightforward: bring the electrocardiogram out of the hospital and into the places where patients already are.
The Problem: A System Clogged With Unnecessary Referrals
To understand why HeartEye matters, it helps to understand the structural problem it addresses. In the Netherlands, 65% of patients who visit a cardiologist after being referred by their general practitioner (GP) turn out not to need specialist care [1]. That means the majority of cardiology referrals — each one requiring a hospital appointment, administrative processing, and specialist time — are, in retrospect, unnecessary. For a healthcare system already under pressure, this represents a significant and avoidable drain on resources. The bottleneck is partly diagnostic: without access to immediate ECG testing, GPs have limited tools to determine on the spot whether a patient’s heart symptoms warrant urgent specialist attention or can be managed in primary care. A standard ECG procedure, when conducted through traditional hospital-based equipment, typically takes between 5 and 15 minutes and requires trained personnel, adhesive electrodes, and a wired setup [1]. It also requires the patient to travel to a hospital or clinic — a logistical barrier that adds delay at precisely the moment when speed can matter most. An electrocardiogram works by recording the heart’s electrical signals in real time; electrodes placed on the chest, arms, and legs capture wave patterns — including the P wave, the QRS complex, and the T wave — that together allow clinicians to identify arrhythmias, tachycardia, and other cardiac abnormalities [2].
How HeartEye’s Device Works — and What Makes It Different
HeartEye has developed a compact, wire-free, and adhesive-free 12-channel ECG recorder capable of producing a full cardiac reading in under one minute [1]. That represents a meaningful acceleration compared to the conventional 5-to-15-minute procedure [1]. The device is designed to be used not only by GPs in their consulting rooms, but also by practice nurses and — notably — in patients’ own homes [1]. The elimination of cables and adhesive electrodes is not a cosmetic improvement; it directly reduces the need for specialist training, removes setup complexity, and makes the device practical in non-clinical environments. Once a recording is captured, the data can be shared digitally, enabling remote cardiological support without the patient needing to leave their home or GP practice [1]. This remote support element is particularly significant: it means that a GP with no specialist cardiology training can, in principle, obtain near-instant expert input on a cardiac reading taken at the point of care. For context on what these readings can detect: ECG analysis can identify tachycardia — defined as a resting heart rate exceeding 100 beats per minute — as well as distinguishing between atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation, each of which produces a distinct wave pattern on the ECG trace [2]. The ability to make these distinctions quickly and outside a hospital setting is the clinical core of HeartEye’s value proposition.
The Person Behind the Device: Tjebbe Tauber’s Unlikely Path From Banking to Cardiac Care
HeartEye was not founded by a cardiologist. Approximately four years ago — around 2022 — Tjebbe Tauber made a deliberate career shift from the banking sector to take on the role of CEO at HeartEye, with the explicit goal of advancing early cardiac diagnostics outside hospital settings [1]. The personal tension he describes is revealing: “The great irony for me personally is that I left the bank to focus on better care for patients, and I’m still thinking a lot about euros” [1]. Tauber’s background in finance has not, it seems, been left entirely behind — and arguably, it is an asset. Bringing a medical device to market requires not only clinical validation but also the construction of sustainable business models for healthcare providers, an understanding of investment cycles, and the discipline to stay focused on the commercial phase that actually matters at any given moment. HeartEye has to date raised over €1.5 million to support the early detection of heart conditions [1]. The company has taken a structured, phase-conscious approach to commercialization, participating in the Market Readiness Program run by GO!-NH through regional development organization ROM InWest [1]. That program, Tauber explains, “focuses you on the phase your company is in” [1]. For HeartEye right now, that means validating product-market fit — not generating revenue from clinical use, since the company has not yet obtained the medical certification required to sell the device for care delivery [1].
Certification, Early Access, and the Road to Scale
HeartEye’s immediate priority is obtaining CE marking — the European regulatory certification that would permit the device to be sold for clinical use [1]. Until that certification is in place, the company is conducting its validation work without being able to commercially deploy the recorder in patient care [1]. In preparation for the post-certification phase, Tauber and his team have already identified their initial target customer: the GP. This conclusion was reached through extensive interviews with healthcare professionals [1]. Once CE marking is secured, HeartEye plans to launch an early access program with a select group of innovative GPs, with a target retention threshold of at least 80% continued usage before scaling further [1]. The intended expansion path extends well beyond GP practices. HeartEye has identified ambulance personnel, disability care settings, and international markets as subsequent target segments [1]. On May 26, 2026, the company announced the formation of a new Advisory Board — comprising Pim Berger, Jeroen Tas, Hans van Snellenberg, Sara Schaafsma, and Dick Sietses — to support the strategic rollout of the device, and confirmed it is accepting its first pre-orders [4][alert! ‘CE certification status and exact pre-order launch date not confirmed in source material as of article date of 6 June 2026’]. This expansion trajectory reflects a broader pattern visible across the global healthtech sector: in Q1 2026 alone, digital health ventures attracted $7.1 billion in funding across 216 deals globally [4], underscoring robust investor appetite for innovations that decentralize and digitize healthcare delivery.
Why This Could Matter for Healthcare Costs — and for Patients
The economic case for HeartEye’s device, once certified and deployed, is grounded in a straightforward logic: if 65% of cardiology referrals in the Netherlands are currently deemed unnecessary after the fact [1], then a tool that allows GPs to triage cardiac concerns at the point of first contact — within one minute, without hospital infrastructure — has the potential to substantially reduce that referral rate. Every avoided unnecessary referral represents saved specialist time, reduced patient travel, lower administrative burden, and faster resolution for the patient. Tauber frames his mission in unambiguous terms: “I know what I’m doing it for: reducing mortality from heart problems by improving diagnostics and keeping care efficient, affordable, and accessible” [1]. The device also addresses a practical staffing reality in Dutch primary care: it requires no adhesive electrodes and minimal personnel training, and it includes access to remote cardiological support [1] — meaning that smaller practices, or those in areas with fewer specialist resources, are not excluded from its benefits. In a healthcare landscape where chronic disease is projected to account for 75% of healthcare spending by 2035 [4], tools that enable earlier, cheaper, and more geographically flexible diagnosis are not peripheral innovations — they are increasingly central to how sustainable healthcare systems will be built.